On 7 AUG OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced second quarter 2014 financial results. Revenue for the three and six months ended June 30, 2014 was $4.9 million and $16.7 million, respectively.  This compares with $6.3 million and $11.4 million, respectively, in the same periods in 2013. Revenue earned in the second quarter of 2014 consists of reimbursable clinical trial, manufacturing and preclinical costs incurred by … Continue reading Hot Watch List: OncoGenex Pharmaceuticals (NASDAQ:OGXI), Enanta Pharmaceuticals (NASDAQ:ENTA), Cheesecake Factory Incorporated (NASDAQ:CAKE), Randgold Resources Limited (NASDAQ:GOLD), OvaScience, Inc. (NASDAQ:OVAS)